CLINICAL_TRIALS
trial_result
· 2021-01-28
Clinical Trial Update: Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions [Phase 2]
Summary
Phase 2 trial evaluating pyrotinib plus thalidomide in advanced non-small-cell lung cancer with HER2 exon 20 insertions.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shanghai Chest Hospital | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN